Askgene Pharma Inc.

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Genentech, Inc.

Jiangsu Aosaikang Ph

Amgen Inc.

Jian-Feng Lu

Yuefeng Lu

Kurt Shanebeck

Lan Yang

Lu Li

Donggou He

David E Allison

Rene Bruno

Chen Yao

Chee M Ng

Lei Liu

Aijun Wang

Shiwen Zhang

Ian Mccaffery

Chunxiao Yu

Fang Xia

Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

Antibodies and methods for making and using the same

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

Angiopoietin 2, VEGF dual antagonists

Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

IL-15 prodrugs and methods of use thereof

The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.

Feline erythropoietin receptor agonists

The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.

PD-L1 specific monoclonal antibodies for disease treatment and diagnosis

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

Growing community of inventors

Oak Park, CA, United States of America

Jian-Feng Lu